Antonio Antela

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Sharon Walmsley, Antonio Antela, Nathan Clumeck et al. · New England Journal of Medicine · 2013 · 856 citations · Full text

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

Estebán Martínez, María Larrousse, Josep M. Llibre et al. · AIDS · 2010 · 191 citations

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +9

Risk Factors for Development of Tuberculosis after Isoniazid Chemoprophylaxis in Human Immunodeficiency Virus--Infected Patients

José L. Casado, Santiago Moreno, Jesús Fortün et al. · Clinical Infectious Diseases · 2002 · 22 citations · Full text

Pulmonary Tuberculosis, Treatment And Prevention, Isoniazid Chemoprophylaxis +10

Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences

José Ramón Santos, José Luís Blanco, Mar Masiá et al. · Journal of Antimicrobial Chemotherapy · 2015 · 17 citations · Full text